Aimmune Therapeutics (NASDAQ:AIMT)‘s stock had its “outperform” rating reaffirmed by investment analysts at Wedbush in a research report issued to clients and investors on Monday.

Several other brokerages also recently commented on AIMT. BidaskClub raised shares of Aimmune Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, December 27th. Credit Suisse Group set a $45.00 target price on shares of Aimmune Therapeutics and gave the company a “buy” rating in a research note on Thursday, January 11th. ValuEngine downgraded shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Zacks Investment Research downgraded shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, January 8th. Finally, Piper Jaffray Companies increased their price objective on shares of Aimmune Therapeutics from $38.00 to $60.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 5th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company’s stock. Aimmune Therapeutics has a consensus rating of “Buy” and an average price target of $57.25.

Shares of Aimmune Therapeutics (NASDAQ AIMT) opened at $37.84 on Monday. Aimmune Therapeutics has a 12 month low of $15.97 and a 12 month high of $40.65. The company has a market cap of $1,975.03, a P/E ratio of -16.10 and a beta of -0.82.

Aimmune Therapeutics (NASDAQ:AIMT) last issued its earnings results on Monday, November 6th. The biotechnology company reported ($0.63) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.72) by $0.09. equities analysts predict that Aimmune Therapeutics will post -2.51 earnings per share for the current fiscal year.

In other news, insider Daniel C. Md Adelman sold 3,283 shares of the stock in a transaction on Wednesday, December 27th. The shares were sold at an average price of $40.00, for a total transaction of $131,320.00. Following the completion of the sale, the insider now owns 3,283 shares of the company’s stock, valued at $131,320. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Douglas T. Sheehy sold 1,648 shares of the stock in a transaction on Thursday, January 4th. The stock was sold at an average price of $37.33, for a total transaction of $61,519.84. Following the sale, the insider now directly owns 1,648 shares of the company’s stock, valued at approximately $61,519.84. The disclosure for this sale can be found here. Insiders have sold 134,294 shares of company stock valued at $5,097,144 in the last three months. 17.59% of the stock is owned by insiders.

Several hedge funds have recently modified their holdings of the company. American International Group Inc. boosted its holdings in Aimmune Therapeutics by 8.1% during the third quarter. American International Group Inc. now owns 23,591 shares of the biotechnology company’s stock worth $585,000 after purchasing an additional 1,764 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in Aimmune Therapeutics by 3.1% during the fourth quarter. Wells Fargo & Company MN now owns 63,158 shares of the biotechnology company’s stock worth $2,388,000 after purchasing an additional 1,892 shares during the last quarter. Daiwa SB Investments Ltd. boosted its holdings in Aimmune Therapeutics by 44.5% during the fourth quarter. Daiwa SB Investments Ltd. now owns 7,290 shares of the biotechnology company’s stock worth $276,000 after purchasing an additional 2,245 shares during the last quarter. SG Americas Securities LLC boosted its holdings in Aimmune Therapeutics by 54.7% during the third quarter. SG Americas Securities LLC now owns 8,430 shares of the biotechnology company’s stock worth $209,000 after purchasing an additional 2,979 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in Aimmune Therapeutics by 2.5% during the third quarter. Bank of New York Mellon Corp now owns 134,614 shares of the biotechnology company’s stock worth $3,337,000 after purchasing an additional 3,261 shares during the last quarter. 73.14% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Aimmune Therapeutics (AIMT) Stock Rating Reaffirmed by Wedbush” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://www.thecerbatgem.com/2018/02/14/aimmune-therapeutics-aimt-stock-rating-reaffirmed-by-wedbush.html.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.